Why activated protein C was not successful in severe sepsis and septic shock: are we still tilting at windmills?

@article{Lai2013WhyAP,
  title={Why activated protein C was not successful in severe sepsis and septic shock: are we still tilting at windmills?},
  author={Peggy S Lai and Boyd Taylor Thompson},
  journal={Current infectious disease reports},
  year={2013},
  volume={15 5},
  pages={407-12}
}
Drotrecogin alpha activated (DAA), trade name Xigris, is a recombinant human protein C that has been the subject of controversy since 2001, when it became the first biologic agent approved for the treatment of severe sepsis and septic shock. The PROWESS trial showed a 6.1 % absolute reduction in 28-day mortality, although these findings were not replicated… CONTINUE READING